Introduction {#S0001}
============

Antibiotics have significant impacts on health care since their first introduction in the early 20th century. While their irrational use in human medicine and animal husbandry resulted in the emergence and rise of antimicrobial resistance genes (ARGs). Polymyxins serve as the last-line refuge against multidrug-resistant (MDR) Gram-negative bacterial infections. Unfortunately, the discovery of *mcr-1* exacerbates the failure in clinical treatment.[@CIT0001] Since then, the dissemination of transferable colistin resistance genes, which involves different ecological niches, bacterial species, replicon types and *mcr*-like variants,[@CIT0002] has been increasingly reported in over forty countries covering six continents.[@CIT0003] More alarmingly, the detection of coexistence of *mcr-1* and *bla*~NDM-5~ in clinical isolates heightened the challenge of the treatment in clinical therapy.[@CIT0004] The global distribution of *mcr-1* gene has captured the attention of public health communities and efficient strategies are needed to be formulated.

ARGs, often present on mobile genetic elements, can be transferred among bacteria, which led to the global prevalence of antibiotic-resistant bacteria and the demand for novel treatment strategies.[@CIT0005] The search of plasmid curing inspired us to remove plasmid from antimicrobial-resistant (AMR) bacteria. However, most traditional plasmid curing methods, such as high temperature, detergents, biocides, DNA intercalating agents and plant-derived compounds, may favor irrespective chromosome mutation or produce unwanted toxic and side effects.[@CIT0006] In recent years, the CRISPR-Cas9 system has been opened new avenues for plasmid curing. It can be designed to target specific sequences of plasmid rather than cure plasmid without discrimination.[@CIT0007]

Clustered regularly interspaced short palindromic repeats (CRISPR) together with CRISPR-associated (Cas) proteins constitute the adaptive immune system of bacteria and archaea, which allows recognition, degradation and memory of foreign DNA sequences.[@CIT0008] Notably, over the past 10 years, the type II CRISPR-Cas system has become the predominant choice for genome engineering applications,[@CIT0009] which requires only the co-expression of Cas9 protein and two RNAs that guide Cas9 to the target site in the invading DNA for subsequent recognition and cleavage.[@CIT0010] Since the two RNAs were further improved into a chimeric, single guide RNA (sgRNA), genome editing with Cas9 has become simpler. After the sgRNA targets specific sequences and recruits Cas9 protein to form the compound, the Cas9 protein acts as a nuclease and generates a blunt end double-strand break (DSB). Owing to the lack of the error-prone non-homologous end-joining (NHEJ) pathway in prokaryotes, Cas9-mediated DSB cannot be repaired spontaneously, so that the DSB occurs in plasmid sequence triggering plasmid curing.[@CIT0010] Based on the CRISPR-Cas9 system, reported studies have been transformed *E. coli* with plasmids that coded sgRNAs to specifically cleave quinolone resistance gene and Extended-spectrum β-lactamases (ESBLs) resistance gene, respectively.[@CIT0011],[@CIT0012] Together, using the CRISPR-Cas9 system to resensitize colistin-resistant *E. coli* by curing *mcr-1*-carrying plasmid is considered as a potentially effective method to resist the dissemination of colistin resistance genes.

It is time to develop unique approaches to combat the dissemination of *mcr-1* gene because of possible breach of the last group of antibiotics, polymyxins, by plasmid-mediated resistance.CRISPR-Cas9 technology provides a novel strategy to target any resistance gene and keep the original colony ecologically stable. Given that the threats of *mcr-1* gene and the advantages of CRISPR-Cas9 system, this study constructed a recombinant plasmid, which holds all functional parts to recognize and degrade targeting sequences, for eliminating *mcr-1* gene and relieving the stress of ARGs. And then we showed the feasibility of the method and explained unexpected escape mutants during the experiment. In conclusion, the study developed a one-plasmid mediated CRISPR-Cas9 system for genome editing in *E. coli* and offered an appealing option to eliminate *mcr-1* gene.

Materials and Methods {#S0002}
=====================

Bacterial Strains and Plasmids {#S0002-S2001}
------------------------------

All strains and plasmids used in this study are listed in [Table 1](#T0001){ref-type="table"}. *E. coli* DH5α was used to be made chemically competent cells and transformed via heat shock. Porcine *E. coli* strain SHP45,[@CIT0001] which is a wild strain containing the *mcr-1* gene and *E. coli* C600 were employed for conjugation experiments. Transconjugants *E. coli* C600+pHNSHP45 were screened on Luria-Bertani (LB) agar plates containing colistin (2 mg/L) and streptomycin (2000 mg/L). The plasmid pCas9 (Addgene: \#42876) was obtained from commercial sources conferring chloramphenicol resistance.[@CIT0013] *E. coli* strains were grown in LB broth and agar plates at 37°C. If necessary, the following antibiotics were supplemented at the different concentrations: colistin (2 mg/L), chloramphenicol (50 mg/L), ampicillin (50 mg/L) and streptomycin (2000 mg/L).Table 1Bacterial Strains and Plasmids Used in This StudyBacterial Strains or PlasmidsRelevant CharacteristicsSource or ReferenceBacterial Strains *E. coli* DH5αF-, φ80dlacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1, endA1, hsdR17(rk-, mk+), phoA, supE44, λ-, thi-1, gyrA96, relA1Laboratory stock *E. coli* C600F- tonA21 thi-1 thr-1 leuB6 lacY1 glnV44 rfbC1 fhuA1 λ-Laboratory stock *E. coli* ATCC 25922Quality control strains for antimicrobial susceptibilityLaboratory stock *E. coli* SHP45Isolated from pig with colistin resistance plasmid(Liu et al, 2015)[@CIT0001]Plasmids pHNSHP45*mcr-1*-harboring IncI2-type plasmid(Liu et al, 2015)[@CIT0001] pCas9 (Addgene,42876)Cm^r^, pSC101 ori, cas9 expression plasmid(Su et al, 2016)[@CIT0013] pUC19Amp^r^, pUC oriLaboratory stock pCas9-m1Cm^r^, pCas9 cloned with sgRNA1 targeting *mcr-1*In this study pCas9-m2Cm^r^, pCas9 cloned with sgRNA2 targeting *mcr-1*In this study pUC19-*mcr-1*Amp^r^, pUC19-*mcr-1* derivative with *mcr-1* geneIn this study[^2]

Plasmid Construction {#S0002-S2002}
--------------------

All oligonucleotides used in this work are shown in [Table 2](#T0002){ref-type="table"}. Plasmids were constructed using standard molecular biology techniques. Firstly, two pairs of sgRNAs (sgRNA1-F/R, sgRNA2-F/R) targeting the *mcr-1* gene were designed by the CHOPCHOP tool. Two targeted sgRNA sequences with different lengths, 20 nt or 30 nt, were synthesized in oligonucleotides with the sticky ends AAAC or G adding at the beginning or end of the forward oligos, respectively, while AAAC was added at the beginning of the reverse oligos. The paired oligonucleotides were then annealed and ligated to the BsaI-digested pCas9 using T4 DNA ligase (NEB), resulting in pCas9-m1 and pCas9-m2, respectively. The recombinant plasmids were transformed into competent *E. coli* DH5α, and the transformants were incubated at 37°C overnight and selected on a plate containing 50 mg/L chloramphenicol. The spacer sequence was confirmed by colony PCR using the primers DR-JD-F/R. And the plasmid pCas9, which does not have the sgRNA cassette, was used as a control plasmid. In order to obtain restructured high copy *mcr-1* plasmid, DNA segment containing the promoter and *mcr-1* gene was amplified from *E. coli* SHP45 template DNA using primers SacI-*mcr-1*-F/R, followed by digestion with SacI and ligated into the corresponding site in pUC19, yielding pUC19-*mcr-1*. We verified both of recombinant plasmids by PCR and further sequencing.Table 2Primers Used in This StudyPrimer NamePrimer Sequences (5ʹ-3ʹ)sgRNA1-FAAACAAAGCTGTTTGATGTCACCGGsgRNA1-RAAAACCGGTGACATCAAACAGCTTTsgRNA2-FAAACCGACATTATTAAAGCTGTTTGATGTCACCGGsgRNA2-RAAAACCGGTGACATCAAACAGCTTTAATAATGTCGDR-JD-FCACGCATTGATTTGAGTCAGDR-JD-RGGTGATGTCGGCGATATAGG*mcr-1*-JD-FTCGCGGCATTCGTTATA*mcr-1*-JD-RGGTGGCGTTCAGCAGTCSacI-*mcr-1*-F*ataaaa***GAGCTC**CGAAGCACCAAGACATCAASacI-*mcr-1*-R*aaaata***GAGCTC**ATACGGCATAACAAACCCC*mcr-1*-qPCR-FACACTTATGGCACGGTCTATG*mcr-1*-qpcr-RGCACACCCAAACCAATGATAC16S-qPCR-FAAGTTAATACCTTTGCTCATTGAC16S-qPCR-RGCTTTACGCCCAGTAATTCCM13-FAGCGGATAACAATTTCACACAGGAM13-RCGCCAGGGTTTTCCCAGTCACGAC[^3]

Plasmid Transformation Assays {#S0002-S2003}
-----------------------------

The competent cells including *E. coli* DH5α containing pUC19-*mcr-1* and *E. coli* C600+pHNSHP45 were prepared and used for transformation assay following the protocol.[@CIT0014] Mixing 100 μL of chemically competent cells with 10 μL of plasmid pCas9-m1 or pCas9-m2 incubated the reaction mixture on ice for 30 min, and subsequently transferred the cells to a constant temperature water bath set at 42°C for 90 s and finally incubated on ice for 2 min. Following transformation, the cells were suspended in 1 mL LB broth and then maintained at 37°C with vigorous shaking (200 rpm) for 1 h. Gradient dilutions of cells were placed on LB agar plates containing 50 mg/L chloramphenicol for selecting the transformants, after standing to dry the plates were inverted cultured at 37°C overnight. The empty plasmid pCas9 was used as negative control.

Editing Efficiency Evaluation {#S0002-S2004}
-----------------------------

After transformation, 24 colonies were randomly picked for evaluating the editing efficiency in each experiment. Primers *mcr-1*-JD-F/R were used to screen the colonies with target gene deletion by PCR. The strain with *mcr-1* gene was used as a positive control. PCR-confirmed original strains and corresponding deletion strains were subjected to antimicrobial susceptibility tests. The minimum inhibitory concentration (MIC) of colistin was performed by broth microdilution method in accordance with the guidelines of Clinical and Laboratory Standards Institute (2018).[@CIT0015] *E. coli* ATCC 25922 was routinely used as a quality control strain.

In order to further analyze the efficiency of pCas9-m1/m2 on removing *mcr-1* gene, the pUC19-*mcr-1* copy numbers at each time point were determined by qPCR. Genomic DNA was extracted using TIANamp Bacteria DNA Kit (Tiangen, Beijing, China). qPCR was performed using SYBR Premix *ExTaq* II (Takara, Dalian, China) with primers specific for *mcr-1* gene and chromosomal 16S ribosomal RNA (16S rRNA) gene. All reactions were run in triplicate. The 2^−ΔΔCT^ method was used to calculate the change of pUC19-*mcr-1* copy number in the experimental group compared to the control group.

Conjugation Assays {#S0002-S2005}
------------------

Conjugation experiments were performed using colistin-resistant *E. coli* C600+pHNSHP45 as the donor and chloramphenicol-resistant *E. coli* C600+pCas9-m1 or C600+pCas9 as the recipient strain as mentioned before.[@CIT0016] In brief, donor and recipient strains grown in suspension overnight and then were diluted 1:100 in fresh LB broth and incubated to an OD600 \~0.4 at 37°C. Then, the cultures were mixed at a donor/recipient ratio of 1:4 (vol/vol) and grown for 24 h. Serial dilutions of the mixtures were placed on LB agar plates supplemented with chloramphenicol and colistin to select for transconjugants. After incubation for 24 h, enumerated the number of colony-forming units (CFU).

Sequencing of Escape Mutants {#S0002-S2006}
----------------------------

Transformants spread on LB agar plates with chloramphenicol were subcultured on another plate containing colistin and we found that a few survivors grew thereon. Then, plasmid DNA from each escape mutant was extracted using EasyPure HiPure Plasmid MiniPrep kits (TransGen, Beijing, China) for sequencing analysis. To analyze the PAM-flanking sequence, approximately 500bp nearby the protospacer within the *mcr-1* gene of each escape mutant was amplified using PCR and subjected to DNA sequencing.

Statistical Analysis {#S0002-S2007}
--------------------

All the experiments described above were repeated at least three times. All statistical analyses were performed using GraphPad Prism version 7.0 (GraphPad Software Inc., San Diego, CA, USA). P values were calculated using the Student's *t*-test, and P \< 0.05 were considered statistically significant.

Results {#S0003}
=======

Construction of CRISPR-Cas9 Plasmids Targeting *mcr*-1 Gene and Recombinant High Copy Plasmids {#S0003-S2001}
----------------------------------------------------------------------------------------------

At first, plasmid pCas9 which contains essential elements including the gene cassettes expressing *Streptococcus pyogenes* Cas9, tracrRNA and crRNA, so that we chose it as the backbone to construct the engineered pCas9 specific to *mcr-1* gene. Oligonucleotides with 20 nt or 30 nt sgRNA sequences replaced the crRNA coding sequences of pCas9, yielding pCas9-m1 and pCas9-m2, respectively ([Figure 1](#F0001){ref-type="fig"}). Additionally, in order to obtain high copy plasmid containing *mcr-1* gene, plasmids pUC19, which has higher copy number compared to its parent plasmid pBR322, was selected as the backbone to construct the high copy numbers plasmid harboring *mcr-1* gene.Figure 1Plasmid map of pCas9-m1/m2 targeted to *mcr-1* gene. The pCas9-m1/m2 was constructed by inserting spacer targeting the *mcr-1* gene along with other essential modules for CRISPR-Cas9 activity.

Elimination of Plasmid Using the Engineered CRISPR-Cas9 System {#S0003-S2002}
--------------------------------------------------------------

To estimate whether CRISPR-Cas9 system can eliminate plasmid from *E. coli*, the control vector pCas9 and the engineered vector pCas9-m1 were transformed into competent *E. coli* C600+pHNSHP45. The results showed that the 582bp fragment indicating the presence of *mcr-1* gene failed to be amplified from 18/24 colonies transformed with pCas9-m1 ([Figure 2A](#F0002){ref-type="fig"}). Meanwhile, 6 colonies still have *mcr-1* gene, defined as escape mutants. For antimicrobial susceptibility tests, the colistin MIC of knockout strain was 0.25 mg/L, which was 6 times lower than that of wild-type (2 mg/L).Figure 2(**A**) Confirmation of *mcr-1* gene presence in *E. coli* C600+pHNSHP45 by PCR amplification with primer *mcr-1*-JD-F/R. The M means 2000bp marker. The + lane is a C600+pHNSHP45 strain transformed with pCas9 as positive control. The other lanes mean C600+pHNSHP45 strain transformed with pCas9-m1 (**B**) Confirmation of *mcr-1* gene elimination in C600+pUC19-*mcr-1* by PCR amplification with primer *mcr-1*-JD-F/R.

The inadequate knockout efficiency suggested us that whether different backgrounds of plasmid containing the interested gene would be an influencing factor, so we generated high copy plasmid pUC19-*mcr-1* based on pUC19 backbone. The competent cells of *E. coli* C600+pUC19-*mcr-1* were used as host and transformed with pCas9-m1. The colony PCR showed that 24 colonies were *mcr-1* negative ([Figure 2B](#F0002){ref-type="fig"}).

To demonstrate whether the efficacy of CRISPR-Cas9 is affected by the length of sgRNA sequence, we constructed the pCas9-m2 containing 30 nt sgRNA targeting *mcr-1*. The pCas9-m2 was transformed into competent cell of *E. coli* C600+pUC19-*mcr-1*. The colony PCR results indicated that the efficacy of pCas9-m2 was not significantly different from that of pCas9-m1.

In order to more accurately evaluate editing efficiency, the relative copy number of plasmid at each time point in pCas9-m1 or pCas9-m2 treated group and pCas9 control group was determined by qPCR. Significant differences in plasmid copy numbers can be seen between the experimental and control groups ([Figure 3](#F0003){ref-type="fig"}). The elimination efficiency of two experimental groups was greater than 80% at the 8th hour and continued until the 24th hour, which clearly indicates that the engineered CRISPR-Cas9 system can effectively eliminate *mcr-1* gene and the length of sgRNA sequence has no significant effect.Figure 3The relative copy number of plasmid pUC19-*mcr-1* at each time point. pCas9-m1 and pCas9-m2 transformed into competent *E. coli* C600+pUC19-*mcr-1* serve as experimental groups. Plasmid pCas9 transformed into competent *E. coli* C600+pUC19-*mcr-1* is control group. The bars represent mean value of three biological replicates with error-bars showing standard deviation.

The Engineered CRISPR-Cas9 System in Bacteria Blocks Plasmid Conjugation {#S0003-S2003}
------------------------------------------------------------------------

Bacterial conjugation is an important way to mediate the horizontal transfer of resistance genes. The CRISPR-Cas system is an adaptive immune system of bacteria and archaea, which can generate immune memory to foreign DNA. We hypothesized that the engineered CRISPR-Cas9 system in bacteria could block plasmid conjugation. The *E. coli* C600 was transformed with a control plasmid pCas9 lacking the target sgRNA or a recombinant plasmid pCas9-m1 targeting *mcr-1* gene, which was used as recipient. The *E. coli* C600 carrying the conjugation plasmid pHNSHP45 was used as a donor. As shown in [Figure 4](#F0004){ref-type="fig"}, the *E. coli* C600 containing plasmid pCas9-m1 reduced the number of transconjugants by 67-times compared to the control plasmid pCas9 (1.68 + E06 vs 2.5 + E04 CFU/mL; p=0.0022). The results demonstrated that the engineered CRISPR-Cas9 system in the recipient cell could block the horizontal transfer of the conjugative plasmid pHNSHP45.Figure 4*E. coli* strain C600 harboring pCas9-m-1 limited the conjugation of pHNSHP45. Colistin-resistant *E. coli* C600+ pHNSHP45 as donor and *E. coli* C600, chloramphenicol-resistant, *E. coli* C600+pCas9-m1 or C600+pCas9 as the recipient strain. Double asterisk indicates statistical significance with P\< 0.01 in Student's *t*-test, compared to the results from *E. coli* C600+pCas9-m1. The bars represent mean value of three biological replicates with error-bars showing standard deviation.

Escape Mutants Analysis {#S0003-S2004}
-----------------------

As mentioned before, when pCas9-m1 was transformed into *E. coli* C600+pHNSHP45, there were 6/24 colonies still resistant to colistin. To initially explore the basis of escape, we inoculated 6 colonies for further analysis and extracted plasmids from escape mutants for sequencing. The result showed that mutants escaped through spacer mutations in the CRISPR locus, deletions in tracrRNA and transposon insertions in Cas9 as presented in [Figure 5](#F0005){ref-type="fig"}. No mutants were observed in the protospacer within the *mcr-1* gene of each escape mutant. In total, an integral active endonuclease, tracrRNA and crRNA are necessary and sufficient to mediate *mcr-1* gene elimination in *E. coli*.Figure 5Characterization of escape mutants that tolerated transformation of pCas9-m1 construct. Spacer mutations in the CRISPR locus, deletions in tracrRNA and transposon insertions in cas9 led to pCas9-m1 inactivation in successful transformants.

Discussion {#S0004}
==========

Antimicrobial resistance is an increasingly serious threat to global public health.[@CIT0017] The emergence and dissemination of colistin resistance *mcr-1* raise a great challenge to the treatment of clinical infections. Since the first report of *mcr-1* in IncI2-type plasmid pHNSHP45, a series of *mcr-1*-carrying plasmids have been detected, including IncHI2,[@CIT0018] IncX4,[@CIT0019] IncX2,[@CIT0020] IncP,[@CIT0021] IncII,[@CIT0022] and other.[@CIT0003],[@CIT0023] The plasmids can act as reservoirs of horizontal gene transfer. Therefore, plasmid curing is an attractive strategy to slow the spread of colistin resistance in bacteria.

Conventional methods for plasmid curing involve growing at high temperatures or adding chemical agents and based on replicon-incompatibility. These methods would generate unwanted mutations, be time-consuming and require precise knowledge about replication of the targeted plasmid.[@CIT0024] CRISPR-Cas system is a bacterial adaptive immune system protecting itself against invaders and has been used in several bacteria such as *E. coli*,[@CIT0025] *Staphylococcus aureus* and *Shewanella algae*.[@CIT0026],[@CIT0027] This system provided an effective strategy for sequence-specific curing of the plasmid.

In this study, we applied CRISPR-Cas9 system into antibiotic-resistant bacteria to eliminate *mcr-1*-carrying plasmid. The results demonstrated that *mcr-1*-positive plasmid in recipient strains can be eliminated, recipient strains are sensitive to colistin and knockout-strain can block the conjugation of initial colistin-resistant plasmid after transformation with CRISPR-Cas9 plasmid targeting *mcr-1* gene. For restructured high copy plasmid pUC19-*mcr-1*, there are no significant differences in curing efficiency with different lengths of sgRNA sequence, presumably caused by identical targeted gene and host. Other study has shown that the knockout efficiency of 17 nt sgRNA in human cells is similar to that of 20 nt sgRNA, but the off-target mutagenic effect is greatly reduced.[@CIT0028] While another study showed that the knockout potency of 17 nt or 20 nt sgRNA was various with different host stem cells and the discrepancy can be explained by differential expression levels of Cas9 in different types of cells.[@CIT0029] These may indicate that the effect of sgRNA sequence length varies from host to host. However, differences in knockout efficiency were observed between pHNSHP45 and pUC19-*mcr-1*, which could be a result of different backbone content. The pHNSHP45 possesses a typical IncI2-type backbone encoding replication, horizontal transfer, maintenance, and stability functions.[@CIT0001] The pUC19 is a commonly used cloning vector and display a relatively high copy-number based on ColE1-like replication machinery. The previous study showed that the curing rates were comparable between the target plasmids with similar backbone but different replicons, while the curing efficiencies varied among the target plasmids with similar replicons but different backbone content.[@CIT0024] Considering variations in copy-number, two other studies showed that there is no clear correlation between copy-number and curing efficiency.[@CIT0024],[@CIT0030] Together, the backbone content of target plasmids is an important factor affecting the curing efficiency.

Compared to other CRISPR-Cas systems, the type II system is the simplest and present only in bacteria.[@CIT0031] The sgRNAs can be designed with multiple spacers simultaneously target different positions of antibiotic-resistant genes. It can also be used to target several genes or various subtypes of drug resistance genes. Targeting diverse locations within the same gene would reduce the probability of CRISPR-escape mutants by the target. And two sgRNAs on a single construct could be used to target and remove both *bla*~NDM-1~ and *bla*~CTX-M-15~ genes, this is significant for reducing the dissemination of multidrug-resistance (MDR).[@CIT0032] In this study, we selected *mcr-1* gene for target, however, 11 more genetic variants of *mcr-1* and additional MCR members have been identified,[@CIT0003] hence further studies are needed to target more genes. The previous study showed that there are many mutations in the sequence of ESBLs, thus they used the homologous regions in TEM and SHV β-lactamases as the target sequence.[@CIT0012] Therefore, the conserved sequence among variants of *mcr-1* or additional MCR members can be selected as a universal target.

The off-target property of CRISPR-Cas system has been a bottleneck for this method in biomedical and clinical applications.[@CIT0033] Combined with experimental and analytical approaches to design optimal sgRNA would improve sgRNA activity and specificity.[@CIT0034] And the efficacy of CRISPR-Cas9 mainly depends on the efficiency of CRISPR-Cas9 system delivering to the target organisms.[@CIT0035] As transformation is a non-spontaneous mode, this form is limited in clinical application. Therefore, multiple other delivery approaches including plasmid conjugation, phagemid and bacteriophages have been used in vitro or in vivo models.[@CIT0025],[@CIT0026],[@CIT0032] In general, the CRISPR-Cas9 system has great potential to reduce the dissemination of antibiotic-resistance and cure infections caused by MDR pathogens.

Conclusion {#S0005}
==========

Our study showed that the engineered CRISPR-Cas9 system could be used to efficiently resensitize resistant isolates to colistin and reduce the horizontal transfer of the conjugative plasmid pHNSHP45. Taken together, the CRISPR-Cas9 system is an attractive alternative against antibiotic resistance and further study optimizing delivery methods are required to improve efficiency in clinical application.
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